For example, the EZH2 PROTACs MS177 and MS8815 have been reported to be effective in inhibiting the growth of breast cancer cells [89] and PROTAC EZH2 degrader-1 in increasing sensitivity to cisplatin, etoposide, and teniposide in small cell lung cancer (SCLC) [90]. This evidence concerns the gene EZH2 and small cell lung carcinoma.